Amicus Therapeutics Q2 EPS $(0.15) Misses $(0.12) Estimate, Sales $94.50M Beat $89.87M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics reported Q2 losses of $(0.15) per share, missing the analyst consensus estimate of $(0.12) by 25%. However, the company's quarterly sales of $94.50 million beat the estimate of $89.87 million by 5.16%. This represents a 17.06% increase over sales from the same period last year.
August 08, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amicus Therapeutics reported a larger than expected loss per share but exceeded sales estimates for Q2.
The mixed results, with a miss on earnings per share but a beat on sales, could lead to neutral short-term price movement for Amicus Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100